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OBJECTIVE—Suppression of Kinesin-1 by antisense oligonu-
cleotides, or overexpression of dominant-negative acting kinesin
heavy chain, has been reported to affect the sustained phase of
glucose-stimulated insulin secretion in -cells in vitro. In this
study, we examined the in vivo physiological role of Kinesin-1 in
-cell development and function.
RESEARCH DESIGN AND METHODS—A Cre-LoxP strategy
was used to generate conditional knockout mice in which the
Kif5b gene is speciﬁcally inactivated in pancreatic -cells. Phys-
iological and histological analyses were carried out in Kif5b
knockout mice as well as littermate controls.
RESULTS—Mice with -cell speciﬁc deletion of Kif5b (Kif5b
ﬂ/:
RIP2-Cre) displayed signiﬁcantly retarded growth as well as
slight hyperglycemia in both nonfasting and 16-h fasting condi-
tions compared with control littermates. In addition, Kif5b
ﬂ/:
RIP2-Cre mice displayed signiﬁcant glucose intolerance, which
was not due to insulin resistance but was related to an insulin
secretory defect in response to glucose challenge. These defects
of -cell function in mutant mice were not coupled with observ-
able changes in islet morphology, islet cell composition, or -cell
size. However, compared with controls, pancreas of Kif5b
ﬂ/:
RIP2-Cre mice exhibited both reduced islet size and increased
islet number, concomitant with an increased insulin vesicle
density in -cells.
CONCLUSIONS—In addition to being essential for maintaining
glucose homeostasis and regulating -cell function, Kif5b may be
involved in -cell development by regulating -cell proliferation
and insulin vesicle synthesis. Diabetes 60:320–330, 2011
I
nsulin is exclusively produced and secreted from
pancreatic -cells in two distinct phases in response
to elevated blood glucose levels. The ﬁrst phase of
insulin release is triggered by a rapid increase of
intracellular calcium level leading to fusion of predocked
insulin granules at the plasma membrane (1). The second
phase of insulin release requires the mobilization of insu-
lin-containing granules from the storage pool to the -cell
periphery to sustain insulin release (2). The molecular
mechanism for the ﬁrst phase of insulin release has been
extensively investigated (1,3–5); however, little is known
regarding the second phase of insulin secretion (6).
Pharmacological and cytological observations suggest
that dynamic turnover of tubulin and microtubules is
important for regulation of intracellular transportation of
insulin granules and their subsequent release from -cells
(7). Boyd et al. (8) observed a proportion of insulin-
containing vesicles attached along the microtubules by
double-immunostaining of primary cultured pancreatic
-cells. Furthermore, colchicine treatment does not affect
the immediate release of insulin but signiﬁcantly attenu-
ates the following sustained phase of response. In addi-
tion, Suprenant and Dentler (9) demonstrated direct
binding of insulin-containing granules to microtubules in
vitro, and that insulin granule movement along microtu-
bules is dependent on microtubule-associated proteins in
the presence of ATP. Therefore, it was suggested that
microtubules within the -cell serve as supporting struc-
tures (railways) upon which insulin granules travel from
the -cell interior to the plasma membrane.
Kinesin and dynein are two motor proteins that have
been identiﬁed to translocate cargos along microtubules to
opposite directions for fast transportation. Conventional
kinesin (Kinesin-1) is a heterotetramer of two heavy
chains (KHCs) and two light chains (KLCs). The head
domain of KHC contains the ATP binding domain for
generating motile force as well as a motif for interaction
with microtubules, whereas the tail domain and KLC are
responsible for cargo binding (10–12). In mice, three
conventional kinesin heavy chain genes have been identi-
ﬁed, including Kif5a, Kif5b, and Kif5c. Kif5b is the mouse
homologue of the human ubiquitous KHC (13) and was
ﬁrst identiﬁed and characterized in pancreatic -cells (14).
The functions and molecular mechanism of kinesin trans-
portation have been extensively studied in neuronal cells
and tissues. However, only a few reports are related to the
role of this motor protein during cargo transportation in
nonneuronal mammalian cell types (15–19). Meng et al.
(20) reported that suppression of Kif5b by antisense
oligonucleotides inhibits both basal- and glucose-stimu-
lated insulin secretion (GSIS) in primary mouse pancreatic
-cells. Immunocytochemistry study showed that Kif5b is
colocalized with some insulin-containing vesicles in -cell
lines (MIN6 & INS-1) (18). Moreover, expression of a
dominant-negative KHC motor domain (KHC
mut) strongly
inhibited the sustained, but not acute, insulin secretion in
response to glucose challenge (18). Besides Kif5b, other
motor proteins such as myosin Va and dynein are also
involved in insulin secretion (21,22).
All the above studies were carried out in an in vitro
model, and the physiological role of Kif5b in pancreatic
-cells has not been elucidated in vivo. Therefore, to
directly explore the role of Kif5b in -cells, we generated
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Cre by using a Cre-LoxP recombination system.
RESEARCH DESIGN AND METHODS
Generation of Kif5b
ﬂ/ﬂ as well as Kif5b
/ mice by gene targeting. A
bacterial artiﬁcial chromosome DNA containing the Kif5b gene (bacterial
artiﬁcial chromosome clone 307D12) was partially digested with XbaI and
subcloned into a pBluescript II-KS plasmid. A plasmid containing a 14.5-kb
DNA insert, pBS-Kif5b, was identiﬁed by Southern blotting using a labeled
probe containing exon 2, where the ATP-GTP-A site is located (data not
shown). The TK4 gene from pBS-304 was cloned into the SalI site of
pBS-Kif5b. The ﬁrst loxP site was introduced into the ﬁrst intron of Kif5b
gene by the recombinogenic targeting of a loxp-Pgk-Tn5-Neo-loxp cassette
(PCR ampliﬁed from the modiﬁed pGK-loxP plasmid with primer: TCTTGT
GACTTAGAGTTTATAAAATAGAGTAATTTTGAAAACACATAGATATCTGCAAAC
CCTATGCTACTCCGTCG and CGCTCTCCTGAGTAGGACAAATCCGCCGGGACT
ATAGGTTGTGTAATGTGTATTTCAAGTCAAAAAATGAATTGAAAAAAA) into
pBS-Kif5b, followed by removal of the fragment between the two loxP sites
via Cre-mediated recombination. The second loxP site accompanying the
frt-Pgk-Tn5-Neo-frt cassette was introduced into the second intron of Kif5b
gene by targeting a frt-Pgk-Tn5-Neo-frt-loxP cassette (PCR ampliﬁed from the
modiﬁed PBS-246-FRT plasmid by PCR primers primer: GGATGCACGGCT
GTGAGCACAGGACTTTCCTGTGTTTGGAGT and primer: AGTTGGATTTA
AGGAAGTACTACTAAAACTTCAATTAGTCTTACTAAAAA) into the pBS-
Kif5b-loxP to form the ﬁnal Kif5b knockout construct. The Kif5b-knockout
construct, containing 14.5 kb of the Kif5b gene, was linearized by NotI and
was introduced into CJ7 mouse embryonic cells in Drs. Jenkins and Copel-
and’s lab in National Cancer Institute (NCI), USA, by electroporation and
screened by genomic Southern blotting. The neo of Kif5b targeted allele
was removed by crossing the mice with a Fple deleter strain
TgN(ACTFLPe)9205Dym/J (23). Kif5b
/ mice were generated by crossing
Kif5b
/ﬂ mice with actin-Cre mice. Mice with Kif5b
ﬂ/ﬂ and Kif5b
/ genotypes
were maintained by backcrossing to C57BL/6N females under a speciﬁc
pathogen-free environment.
Generation of Kif5b conditional knockout mice and genotyping. RIP2-
Cre transgenic mice (24) (from Jackson Laboratory) were ﬁrst crossed with
Kif5b
/ to generate Kif5b
/; RIP2-Cre mice. Then Kif5b
/; RIP2-Cre mice
were bred with Kif5b
ﬂ/ﬂ mice to generate the ﬁnal mutant mice (Kif5b
ﬂ/:
RIP2-Cre) as well as their littermates (Kif5b
/ﬂ, Kif5b
/ﬂ, and Kif5b
/ﬂ:RIP2-
Cre). Genotyping was performed by PCR using corresponding primers. To
avoid hormonal effects in physiological assays, only male animals were used
in all experiments.
Islet isolation and insulin content measurement. Islet isolation and
insulin extraction were carried out as previously described (25). Insulin
contents in the islet extracts were analyzed by using the insulin ELISA kit
(LINCO Research) and normalized to total protein concentrations determined
by Bradford method (Bio-Rad).
Western blot and immunostaining. Protein levels were determined by
blotting with anti-Kif5b primary antibody (1:2,000, against synthesized peptide
FDKEKANLEAFTADKDIA), anti-Kif5a (1:1,000, against synthesized peptide
NGNATDINDNRSDLPC), anti-Kif5c (1:1,000, against synthesized peptide SAK
DQKSLEPC), and anti-actin primary antibody (1:3,000, Sigma). Enhanced
chemiluminescence kit (Pierce) was used for detection of the immunoreactive
bands.
Parafﬁn sections were immunostained by primary antibodies against Kif5b
(1:400), glucagon (1:1,000, Dako), and insulin (1:2,000, Sigma). Visualization of
these proteins was realized by incubating with FITC/Cy3 or HRP-conjugated
secondary antibodies.
Blood glucose and plasma insulin measurement. Blood was obtained from
the tail vein of mice. Blood glucose concentration was determined by
Glucometer Elite (Bayor Inc.). Blood samples were collected by Microvette
CB300 (Sarstedt) and centrifuged at 5,000 rpm for 5 min at room temperature.
After centrifugation, supernatant was collected for determining plasma insulin
levels by using insulin ELISA kit (LINCO Research).
Morphometric analysis. Parafﬁn sections of pancreata were processed for
hematoxylin and eosin staining and observed by a light microscope (Carl
Zeiss). For transmission electron microscopy (TEM) study, isolated islets
were ﬁxed by 2.5% glutaraldehyde in carcodylate buffer and embedded in 2% soft
agar, followed by further embedding in fresh epoxy resin. Ultrathin sections were
examined on a Philips EM208s transmission electron microscope operated at 80
kV. All photos were analyzed by using Image-Pro Plus software.
Quantitation of -cell proliferation rates. -cell division was determined
by 5-bromo-2-deoxyuridine (BrdU) incorporation in 1-month-old mice using
BrdU staining kit (ZYMED Laboratory). Pancreatic parafﬁn sections were
further counterstained by hematoxylin and imaged with a Zeiss Axioskop
microscope to count BrdU
 -cells and total nuclei within islets.
Statistical analysis. SigmaStat (Systat Software) was used to analyze all
data, which were expressed as mean  SE. The data were analyzed by
one-way ANOVA followed by Tukey test or unpaired two-tailed Student t test.
RESULTS
Generation of Kif5b
ﬂ/:RIP2-Cre mice. The ability of
RIP2-Cre to induce pancreatic -cell speciﬁc ablation has
previously been reported when these founder mice were
crossed with mice carrying various ﬂoxed genes including
glucokinase (26), insulin receptor (27), mitochondrial tran-
scription factor A (28), and hepatocyte growth factor (25).
Although RIP2-Cre displays a low level of expression in
the hypothalamus, it exhibits high expression level in
-cells within the pancreatic islet (24). Therefore, condi-
tional knockout of Kif5b mainly occurred in pancreatic
-cells. Figure 1A shows the strategy to generate Kif5b
ﬂ/ﬂ
and Kif5b
/ mice. Ablation of one Kif5b allele was
conﬁrmed by Southern blot as well as Western blot
analyses (Fig. 1B and C). Figure 2A shows the genomic
organization of different Kif5b alleles. P1 and P2 primers
were used to differentiate the wild-type and knockout alleles.
The distance between P1 and P2 was 6.6 kb in length, which
was too long to be ampliﬁed by PCR genotyping. Because of
the deletion of exon 2, a 219-bp PCR product could be
ampliﬁed from the Kif5b knockout allele accordingly (Fig.
2B). P1 and P3 primers, used to differentiate the ﬂoxed and
wild-type Kif5b alleles, result in two bands of 275 and 215 bp,
respectively (Fig. 2B). The RIP-2 Cre transgene was detected
using Cre primers (Fig. 2B).
Kif5b was mainly expressed in pancreatic islets (endo-
crine portion) with little expression in exocrine acinar
glands (Fig. 3A, left). The positive staining was absent
after preincubating the anti-Kif5b antibody with the 18-aa
synthesized peptides (Fig. 3A, right). To test the efﬁciency
of RIP-2-Cre mediated pancreatic -cell speciﬁc deletion
of exon 2 of Kif5b allele, we examined the protein
expression levels of Kif5a, Kif5b, and Kif5c in hypothala-
mus and isolated islets from both mutant and wild-type
mice (Fig. 3B). Inactivation of Kif5b by Cre-induced
ablation resulted in a reduction of Kif5b protein level in
islets, whereas both Kif5a and Kif5c were not detectable in
islets although they are highly expressed in hypothalamus,
consistent with an earlier ﬁnding that their expression is
neuronal speciﬁc (29). Although RIP2-Cre displayed a low
level of expression in the hypothalamus (24), we could not
detect signiﬁcantly decreased Kif5b expression in the
hypothalamus due to Cre expression. In contrast, Western
blot results showed that Kif5b level in the isolated islets
was reduced by at least 80% in mutant mice, compared
with the wild-type. Considering the fact that RIP-2 Cre is
only expressed in 80–90% of -cells and that -cells
account for 75% of islet cells, the Western blot result
indicated that Kif5b was absent in most -cells in the
mutant mice islets. The knockout efﬁciency was further
demonstrated by immunohistochemistry analysis of Kif5b
expression in pancreatic sections under identical conditions.
A signiﬁcant decrease of Kif5b expression was observed in
the islets from mutant mice compared with those in wild-type
mice (Fig. 3C). Taken together, these results suggested that
RIP-2 Cre mediated ablation of exon 2 in Kif5b allele had
efﬁciently occurred, leading to signiﬁcantly reduced Kif5b
expression in the islets of mutant mice.
Kif5b
ﬂ/:RIP2-Cre mice have postnatal growth retarda-
tion. Although there was no signiﬁcant difference in body
weight among newborn mice of different genotypes, the
mutant mice had progressively reduced growth comparing to
J. CUI AND ASSOCIATES
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mice growth curves, the body weight differences between
mutant and control littermates were signiﬁcant (as shown in
the representative photo in Fig. 4B) and there was no
signiﬁcant difference among wild-type and heterozygous con-
trols (Fig. 4A).
Kif5b
ﬂ/:RIP2-Cre mice develop diabetes due to in-
sulin secretion defect. To test the effect of Kif5b condi-
tional knockout on glucose homeostasis, we ﬁrst analyzed
the blood glucose level as well as plasma insulin level in
both mutant mice and littermate controls. Mutant mice
had progressively increased hyperglycemia compared with
control littermates in both random (Fig. 4C) and 16-h
fasting conditions (Fig. 4D) within the investigated ages.
Therefore, 2- to 3-month-old mice were selected for fur-
ther study. Consistent with an elevated glucose level,
mutant mice had lower plasma insulin concentrations in
fasting conditions (Fig. 4F) but not in a random fed state
(Fig. 4E). There were no signiﬁcant differences in the
blood glucose levels as well as plasma insulin concentra-
tions between wild-type and heterozygous controls.
We next assessed the impact of inactivation of Kif5b on
glucose-regulated insulin secretion in vivo (Fig. 5A). The
responses of 2- to 3-month-old mutant mice and control
B C
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FIG. 1. Targeted disruption of the mouse Kif5b gene in ES cells. A: Targeting strategy with positive–negative selection. Strategy of genomic Southern
blot for screening for the homologous recombinant embryonic stem (ES) cell clones is also included. E1, E2, E3, E4, and E5 represent exon 1, exon 2,
exon 3, exon 4, and exon 5 of the Kif5b gene, respectively. EI and EV represent EcoRI and EcoRV cut sites, respectively. The solid square with bars
on each side (the bar representing an frt site) represents the 1.7-kb frt-Neo
R-frt cassette. The triangles represent the LoxP sites (drawing not to scale).
Frt: Flippase recognition target; TK: Thymidine Kinase. B: Southern blotting analysis of targeted ES clones. Restriction enzyme used for screening 5
end recombination events was EcoRV. A 15.5-kb fragment in wild-type and a 7.9-kb fragment after homologous recombination were expected by the 5
external probe. Restriction enzyme used for screening 3 end recombination events was EcoRI. A 6.2-kb fragment in wild-type and a 7.6-kb fragment
in targeted cells were expected by using the 3 external probe. These probes are indicated in panel (A). C: Western blot analysis of Kif5b protein
expression in different tissues in homozygous as well as heterozygous mice for the targeted Kif5b mutation. Actin was used as internal control.
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forming an intraperitoneal glucose tolerance test (GTT)
after 16-h overnight fast. Kif5b
ﬂ/:Cre mice showed slight
glucose intolerance compared with wild-type mice, which
may be due to Cre expression in -cells (30) in addition to
the ablation of one Kif5b allele. Comparison of the GTT
responses between mutant mice and Kif5b
ﬂ/:Cre mice
showed that Kif5b conditional knockout mice had mark-
edly impaired glucose tolerance and this intolerance was
not a result of Cre expression. Although the mutant mice
had hyperglycemia and glucose intolerance compared
with wild-type and Kif5b
ﬂ/:Cre mice, the blood glucose
levels dropped to a similar level as control mice at 15 min
after insulin injection (Fig. 5B).
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FIG. 2. Assessment of conditional Kif5b inactivation in pancreatic -cells of Kif5b
ﬂ/:RIP2-Cre mice. A: Schematic illustration of Cre-mediated
deletion of exon 2 from the Kif5b allele. B: Representative pictures show PCR analysis of the offspring genomic DNA from ear. To detect the
presence of the ﬂoxed Kif5b allele, we used primer P1 5-TGAAGGCTAAGTCAGATATGGATGC-3 located upstream of loxP site and P3
5-TTACTAACTGAACCTGGCTTCCTAG-3 located downstream of loxP site. The presence of Kif5b knockout allele was detected by primer P1
5-TGAAGGCTAAGTCAGATATGGATGC-3 located in intron 1 and P2 5-GGATTGGCACCTTTACCTAGAAGG-3 located in intron 2 of the Kif5b
gene. The RIP-Cre transgenic mice were identiﬁed by ampliﬁcation of Cre allele using primer 5-GGACATGTTCAGGGATCGCCAGGCG-3 and
5-GGCATGTTCAGGGATCGCCAGGCG-3. The PCR bands of wild-type (215 bp), ﬂoxed (275 bp), null allele (219 bp), and Cre (250 bp) are
indicated. Genotypes of representative litters are indicated.
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FIG. 3. A: Immunohistochemistry analysis of Kif5b expression in wild-type mice pancreas sections (left) and antibody speciﬁcity test (right). B:
Western blot analysis of Kif5a/Kif5b/Kif5c expression in hypothalamus and isolated islets from mutant and control mice. C: Immunohistochem-
istry analysis of Kif5b expression level in islets from control (upper) and mutant mouse (lower). (A high-quality color representation of this
ﬁgure is available in the online issue.)
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tion, insulin secretion in response to high glucose chal-
lenge was examined in 2- to 3-month old mice (Fig. 5C). In
wild-type mice, insulin secretion was increased by about
twofold at 2.5 min after intraperitoneal injection of glu-
cose, reaching a peak at about 5 min, and remained higher
than base level for at least 1 h. Glucose tolerance and
insulin release were slightly impaired in Kif5b
ﬂ/:Cre mice
compared with wild-type mice in the ﬁrst 30 min after
glucose injection, but the glucose and insulin levels were
similar in both genotype mice by 60 min. However, both
the early and slow phase of insulin secretion were im-
paired in Kif5b
ﬂ/:Cre mice. These results indicated that
glucose intolerance in Kif5b conditional knockout mice
was not associated with insulin resistance (Fig. 5B) but
was related to an insulin secretory defect in response to
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FIG. 4. Physiological features of Kif5b
ﬂ/:RIP2-Cre mice. A: Growth curves of male mice, wild-type (triangle), heterozygous (square), and mutant
(circle) mice (n  6–12). B: Photograph of 8-week-old control (left) and mutant (right) male mice. C and D: Blood glucose concentrations of male
mice with different ages in nonfasting (C) and 16-h fasted (D) wild-type, heterozygous, and mutant mice (n  8–22). There is no signiﬁcant
difference of the body weight or blood glucose level between wild-type and heterozygous mice, but these values of mutant mice are signiﬁcantly
different from that of wild-type mice with the same ages. *P < 0.05, **P < 0.01. E and F: Plasma insulin levels in nonfasting (E) and 16-h fasted
(F) wild-type (black bar), heterozygous (white bar), and mutant mice (striped bar) (n  6 mice, 2- to 3-month-old). Different letters indicate
statistical difference (P < 0.05). The plasma insulin levels in wild-type and heterozygous mice are not different from each other while they are
statistically different from that of the mutant mice.
POSSIBLE ROLES OF Kif5b IN -CELL FUNCTION
324 DIABETES, VOL. 60, JANUARY 2011 diabetes.diabetesjournals.orgA
C
E
0 20 40 60 80 100 120
0
5
10
15
20
25
30
Time (min)
fl/+
fl/+,Cre
  fl/-,Cre **
**
*
*
0 1 02 03 04 05 0 0
0
2
4
6
8
10
12
14
*
Time (min)
fl/+
fl/+,Cre
  fl/-,Cre
Time (min)
0 1 02 03 04 05 06 0
0.0
0.2
0.4
0.6
0.8
1.0
1.2
* * * *
*
** *
fl/+
fl/+,Cre
  fl/-,Cre
0.0
0.5
1.0
1.5
2.0
2.5
KCl (mM)
3.6 30
p=0.2217
p=0.7141
fl/+
fl/+,Cre
  fl/-,Cre
*
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0 mM 5 mM 10 mM 20 mM
p=0.056
fl/+
fl/+,Cre
  fl/-,Cre
*
*
**
**
Glucose (mM)
0
2
4
6
8
10
12
p=0.183 fl/-,Cre
fl/+
B
D
F
6
B
l
o
o
d
 
G
l
u
c
o
s
e
 
L
e
v
e
l
 
(
m
m
o
l
/
L
)
B
l
o
o
d
 
G
l
u
c
o
s
e
 
L
e
v
e
l
 
(
m
m
o
l
/
L
)
I
n
s
u
l
i
n
 
(
f
o
l
d
 
i
n
c
r
e
a
s
e
)
P
l
a
s
m
a
 
I
n
s
u
l
i
n
 
L
e
v
e
l
 
(
n
g
/
m
l
)
I
n
s
u
l
i
n
 
(
f
o
l
d
 
i
n
c
r
e
a
s
e
)
I
n
s
u
l
i
n
 
(
n
g
/
m
g
 
p
r
o
t
)
FIG. 5. Effect of Kif5b deletion on glucose metabolism. A: Intraperitoneal (i.p.) GTTs were performed on overnight-fasted wild-type (triangle),
heterozygous (square), and mutant mice (circle). After overnight fasting, mice were injected with glucose (2 g/kg body wt i.p.) and blood glucose
levels were monitored immediately before and 15, 30, 60, and 120 min after glucose injection (n  5–6 mice per group, 2- to 3-month-old). Mutant
mice exhibited reduced glucose tolerance compared with wild-type control, as revealed by signiﬁcantly increased blood glucose concentrations
at corresponding time points (*P < 0.05, **P < 0.01). The glucose tolerance ability was not signiﬁcantly affected by half reduction of Kif5b
expression, because there is no difference for the blood glucose level between control and heterozygous mice. B: Insulin sensitivity test was
performed on random-fed mice (n  5–8 mice per group, 2- to 3-month-old). Blood glucose level was measured at the time points indicated before
and after intraperitoneal injection of human regular insulin (0.75 units/kg body wt). Although the blood glucose level is high in mutant mice
before insulin administration, there is no difference of the glucose level after insulin intraperitoneal injection among the three genotype mice.
C: GSIS was carried out on overnight-fasted mice as well as isolated islets. Glucose (3 g/kg) was administrated intraperitoneally to overnight
(16-h) fasted mice (n  5 mice per group, 2- to 3-month-old). Plasma insulin levels were measured at indicated time points. GSIS was signiﬁcantly
diminished by Kif5b knockout. D: In vitro GSIS was carried out on groups of 10 islets of similar sizes obtained from wild-type (black bar),
heterozygous (white bar), and mutant (striped bar) mice and incubated in Krebs-Ringer bicarbonate buffer, supplemented with 10% FBS for 30
min with different glucose concentrations. Experiments were performed in duplicate, and insulin levels were determined by ELISA (n  4–5
groups for each genotype). Signiﬁcant decreases in GSIS were observed in mutant mice islets incubated at 5, 10, and 20 mmol/l glucose compared
with wild-type mice at the same glucose concentration, and there was no difference between wild-type and heterozygous mice under any glucose
concentration. E: Insulin release response to indicated concentrations of KCl treatment (n  3–4 groups for each genotype). Mutant islets
exhibit reduced insulin secretion under the stimulation of high concentration of K
. F: Islet insulin content from control (black bar) and mutant
islets (white bar) (n  5 mice per group). P values are indicated in the ﬁgure. *P < 0.05, **P < 0.01.
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insulin secretion could be secondary, particularly when
considering the expression of Cre in hypothalamic or
pituitary cells. To address this possibility, we studied GSIS
in isolated islets from mice with different genotypes (Fig.
5D). As expected, mutant islets secreted signiﬁcantly less
insulin than control islets under glucose-stimulated condi-
tions. No signiﬁcant difference in insulin secretion was
observed in the absence of glucose. Furthermore, the
insulin-secretion defect was progressively enhanced in
mutant islets with an increase in glucose concentration. A
high level of KCl is known to trigger insulin secretion by
inducing plasma membrane depolarization followed by
Ca
2 inﬂux (1). To further investigate the effect of Kif5b
knockout on insulin secretion, KCl-stimulated insulin re-
lease from islets was analyzed by 30 mmol/l KCl treatment
(Fig. 5E). The wild-type islets exhibited stronger secretory
responses than mutant islets.
To rule out the possibility that insulin is produced at a
lower level in the mutant islet than in the wild-type, an
immunostaining assay was carried out. The result demon-
strated that the insulin level in mutant mouse was not less
than that of wild-type control (Fig. 6A). A quantitative
analysis of islet insulin content was carried out by ELISA
to conﬁrm the result. Results indicated that more insulin
accumulated in mutant islets compared with wild-type,
although the difference was not statistically signiﬁcant
(Fig. 5F). Taken together, it is most likely that the impaired
insulin secretion in mutant mice is due to a primary defect
in -cell function.
Pancreas of Kif5b
ﬂ/:RIP2-Cre mice display de-
creased islet size. Islets from mutant mice showed
similar cellular arrangements and compositions as wild-
type mice, with the majority of cells being -cells and with
glucagon-positive -cells in the periphery region (Fig. 6A).
There were no signiﬁcant differences of - and -cell ratio
between mutant and wild-type islets (Fig. 6B). Because
Kif5b has been reported to transport insulin vesicles in
-cell lines (MIN6 & INS-1) (18) and mitochondria in
neurons (31), we further analyzed the distribution of these
vesicles/organelles in mutant and wild-type -cells by TEM
studies (Fig. 7). Compared with the control, mitochondria
in mutant -cells were found to be more likely to cluster in
the perinuclear region (Fig. 7A). Further quantitative anal-
ysis of the distribution of mitochondria in -cells con-
ﬁrmed that 70% of mitochondria were closer to the nuclear
membrane than to the plasma membrane after Kif5b
knockout whereas mitochondria in wild-type -cells were
evenly distributed in the cells (Fig. 7B). This is consistent
with earlier ﬁndings that Kif5b is involved in mitochondria
translocation (32).
The subcellular localization of insulin vesicles was then
analyzed and found to not be affected signiﬁcantly by the
decreased Kif5b level. The cytoplasm of both wild-type
and mutant -cells were ﬁlled with insulin vesicles. Insulin
vesicle numbers per square m were determined by
counting all insulin vesicles in randomly photographed
-cells (Fig. 7C). More insulin granules were found in
Kif5b knockout -cells compared with control cells. This
phenomenon is consistent with the observation that insu-
lin secretion by -cells is affected. Interestingly, a number
of small islets were observed in mutant mice as shown in
the representative microphotographs in Figure 8A. Quan-
titation of the islet number and size conﬁrmed that the
average size of the islet in mutants was smaller than that of
the wild-type mice (Fig. 8B). However, the total islet mass
was not decreased in Kif5b deﬁcient mice (Fig. 8C),
concomitant with an increase of islet number (Fig. 8D).
Histomorphometric analysis of the size and number of
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FIG. 6. Kif5b
ﬂ/:RIP2-Cre mice had normal islet morphology, islet cell
composition, and -cell size. A slight increase in islet insulin content
was observed. A: Immunoﬂuorescence staining for insulin (green) and
glucagon (red) in control (upper) and mutant mice (lower) (2- to
3-month-old). B: Statistical analysis of - and -cell ratio in control
(black bar) and mutant (white bar) mice (n  3 mice per group);
immunoﬂuorescent staining was carried out on two sections (>300 m
apart) for -cell (red) and -cell (green), and all islets on the sections
were imaged. (A high-quality color representation of this ﬁgure is
available in the online issue.)
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number of islets 	4,000 m
2 was signiﬁcantly increased in
Kif5b conditional knockout mice. However, the number of
islets 
4,000 m
2 in mutant mice was comparable to that
of wild-type control (Fig. 8E). No reduction of islet cell
size was observed in Kif5b deﬁcient mice (Fig. 8F); there-
fore, the major factor accounting for reduced islet size was
reduced cell number in an islet. We analyzed islet cell
proliferation rates in pancreatic sections obtained from
1-month-old mice by BrdU
 labeling. As shown in Figure
8G, islet cell proliferation was reduced by 50% relative
to the wild-type control. There was no detectable in-
crease in islet -cell apoptotic rate based on TUNEL

analysis (supplementary Fig. 1, available in an online
appendix at http://diabetes.diabetesjournals.org/cgi/
content/full/db09-1078/DC1).
DISCUSSION
To study the role of Kinesin-1 in pancreatic -cells in vivo,
we have generated cell-speciﬁc Kif5b-insKO mice (Kif5b
ﬂ/:
RIP2-Cre) by crossing Kif5b
ﬂ/ﬂ mice with Kif5b
/:RIP-
Cre mice, in which Cre recombinase is expressed under
the control of rat insulin gene promoter (RIP2). Although
RIP2-Cre in pancreatic -cells may have some effect on
glucose tolerance in mice (30), this molecular genetic
approach allows in vivo studies of speciﬁc gene function
and could exclude possible side effects of in vitro intro-
duction of anti-kinesin antibodies (33) and overexpression
of dominant-negative-acting kinesin (18), which may inter-
fere with biological processes such as endoplasmic retic-
ulum stress.
This in vivo study reveals that Kif5b plays an important
role for -cell function and development. Kif5b-insKO
mice displayed signiﬁcant glucose intolerance and insulin
secretory defects. Change in -cell function was not
coupled with changes in islet cell size, islet morphology,
and islet cell composition but was associated with a
reduced islet size as a consequence of decreased -cell
proliferation rate.
Kif5b-insKO mice exhibited growth retardation within
the indicated period. Physiological examination found that
Kif5b-insKO mice displayed hyperglycemia and decreased
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FIG. 7. Ultrastructural insights in pancreatic -cell based on TEM study. A: Representative TEM photos of -cell from control (left) and mutant
(right) mice. Nuclei (N) were located centrally in both cells. More mitochondria (arrows) were located near the nucleus in mutant -cells. Insulin
vesicles (arrowheads) were distributed evenly in both mutant and control cells. Scale bar  2 m. B: Statistical analysis of the distribution of
mitochondria in -cell. The x-axis represents the ratio of distances from mitochondria to nucleus and to cell membrane. A ratio <1 indicates that
mitochondria are closer to the nucleus, whereas a ratio >1 indicates that mitochondria are closer to the plasma membrane. The y-axis represents
the percentage of mitochondria in the indicated area. All mitochondria in -cells are recorded. C: Number of insulin vesicles per 1 m
2 in -cells.
(Fifteen and 26 -cells are randomly photographed for wild-type and mutant mice, respectively.) *P < 0.05, **P < 0.01.
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ished glucose tolerance and defective insulin secretion,
suggesting a role of Kif5b in -cell function. Our results
conﬁrm that Kif5b is required for normal GSIS in an in vivo
model. Hypoinsulinemia may account for the poor growth
of Kif5b-insKO mice. However, RIP2-Cre expression in
hypothalamus and pituitary (24,34) may also lead to the
knockout of Kif5b in insulin-positive cells, although no
signiﬁcant reduction of Kif5b level due to Cre expression
was observed in hypothalamic lysates of Kif5b-insKO
mice. The functions of Kif5b in hypothalamic and pituitary
endocrine hormone secretion are unknown at the current
stage. Therefore, we cannot rule out the possibility that the
observed poor growth is also related to reduced growth
hormone and/or insulin-like growth factor secretion.
In vitro studies showed that suppression of Kif5b by
overexpression of dominant-negative-acting Kif5b inhib-
ited only the sustained phase of GSIS in clonal -cells (18).
Interestingly, our in vivo GTT results (Fig. 5A and C)
indicated that the defective insulin response to glucose in
a Kif5b-insKO mouse occurred in both the early phase and
the slow phase. The early phase of insulin secretion is
accompanied by Ca
2 inﬂux induced exocytosis (1), which
requires the metabolism of glucose to create ATP in
mitochondria, leading to depolarization of the cell due to
the closing of ATP-gated potassium channels. Kif5b and
Kif5c have been reported to bind to RanBP2 to determine
mitochondria localization and function in neurons (31). In
the current study, we found that mitochondria signiﬁ-
cantly accumulate at the perinuclear region in the -cell of
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FIG. 8. Kif5b
ﬂ/:RIP2-Cre mice exhibited reduced islet size in pancreas. A: Representative microphotographs of pancreatic sections from a control
(left) and a mutant mouse (right) stained by insulin antibody showed the presence of multiples of small islets. B: Statistical analysis of the
average size of islets in pancreatic samples from control (black bar) and mutant mice (white bar) (all islets in ten whole sections [>300 m apart]
from three wild-type mice and mutant mice were photographed and analyzed). C: Total islet area expressed as the percentage of total pancreas
area. D: Number of islets per 10 mm
2 of total pancreatic area. E: Histomorphometric analysis of the size and number of islets in these pancreatic
samples from control and mutant mice. F: Mean islet cell size in control and mutant mice. G: Frequency of BrdU
 staining nuclei in islets as the
percentage of total islet nuclei (59 and 62 islets corresponding to three wild-type and three mutant mice, respectively, were imaged and counted).
Scale bar  200 m. *P < 0.05. (A high-quality color representation of this ﬁgure is available in the online issue.)
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traembryonic cells upregulated the mRNA expression
level of Kif5a and Kif5c (32), there is no apparent upregu-
lation of Kif5a/Kif5c at the protein level in mutant -cells,
indicating that Kif5b is the major motor responsible for the
dispersion of mitochondria in pancreatic -cells. The
deﬁciency of mitochondria at the cell peripheral regions
may attenuate glucose-to-ATP conversion and partially
account for the defect in the early phase of GSIS in
response to glucose challenge.
To examine whether blocked Kif5b-mediated insulin
vesicle transportation in Kif5b-insKO mice may lead to a
decrease in predocked vesicles ready for exocytosis, we
also performed TEM studies. However, we observed no
signiﬁcant differences in the number and size of predocked
insulin vesicles in Kif5b-insKO mice compared with con-
trol mice at the resolution used. Bi et al. (33) observed that
KHC (or Kif5b) antibody SUK4 as well as the stalk-tail
fragment of KHC speciﬁcally inhibited Ca
2-regulated
exocytosis in Lytechinus pictus sea urchins. Therefore,
exocytosis of insulin vesicles could also be affected in the
Kif5b knockout islet. In neurons, it was demonstrated that
Kif5b can directly bind to syntabulin and SNAP25 to
mediate transportation of syntaxin containing vesicles and
synaptosome (35,36). Syntaxin and SNAP25 constitute the
t-SNAREs at the plasma membrane and are functionally
required for Ca
2-triggered insulin exocytosis in -cells
(37). Snap25 mutant mice had impaired insulin granule
priming, exocytosis, and recycling in pancreatic -cells
(38). It is possible that knockout of Kif5b in pancreatic
-cells affects the normal distribution and function of the
SNARE complex, thereby leading to defects in insulin
granule exocytosis. Furthermore, Kif5b functions in sev-
eral cellular processes including lysosomal distribution
and stability in cancer cells and extraembryonic cells
(32,39), endoplasmic reticulum to Golgi transportation in
Hela cells (40), transportation and axonal targeting of Kv1
channels (41), axonal transport of tubulin heterodimer for
microtubule polymerization (42) as well as ribosome
translocation (43), etc. Similar cellular functions of Kif5b
could occur in pancreatic -cells. It is tempting to specu-
late that weakening of both the early and slow phases of
insulin response to glucose in Kif5b-insKO mice results
from defects in a series of cellular functions after knock-
out of Kif5b in pancreatic -cells. Taken together, Kif5b
probably exerts a modulatory effect in regulating insulin
granule priming and exocytosis in addition to mechani-
cally transporting insulin vesicles. Furthermore, impaired
early insulin response is consistent with a defect in
glucose tolerance, because the early response is more
important for glucose disposal (44). Insulin secretion
defects result in a positive feedback for the synthesis of
insulin in -cells, thereby leading to accumulation of
insulin in Kif5b-insKO mice islets.
Donelan et al. (45) reported that increased [Ca
2]i can
activate calcineurin in -granules leading to dephosphor-
ylation of KHC, which is required for transport of -gran-
ules from the storage pool to replenish the readily
releasable pool of -granules. Rab3A is mainly located on
the cytosolic face of -granule membranes. The Rab3A–
calmodulin interaction on -granules is required for acti-
vation of calcineurin and dephosphorylation of KHC (46).
Yaekura et al. (47) found that knockout of Rab3A in
pancreatic -cells leads to blunted ﬁrst-phase glucose
induced insulin release in vitro and in vivo. Our results
together with these studies indicate that any defect of
synthesis or dephosphorylation process of KHC can lead
to impaired insulin exocytosis.
On the basis of histomorphological investigations, we
found a notable increase in the number of small islets in
Kif5b-insKO mice (Fig. 8A and E). BrdU
 staining of
1-month-old mice conﬁrmed that the decreased islet size in
Kif5b-inskO mice was due to a defect in islet cell prolifer-
ation (Fig. 8G). Furthermore, decreased cell proliferation
rate was also observed in Kif5b deﬁcient Madin-Darby
canine kidney cells (supplementary Fig. 2, available in an
online appendix), suggesting that Kif5b plays a conven-
tional role during cell division. Zhu et al. (48) systemati-
cally analyzed the functions of all human kinesin/dynein
microtubule motor proteins by RNA interference and
identiﬁed at least 12 human kinesins involved in HeLa cell
division. Recently, Haraguchi et al. (49) found that the
kinesin-2 complex (KIF3A/3B) is localized with compo-
nents of the mitotic apparatus such as spindle microtubules
and centrosomes and plays an important role not only in
interphase but also in mitosis. Both Kif5b and KIF3A/B are
microtubule plus end-directed motors for membrane or-
ganelle transportation. Therefore, it is of considerable inter-
est to determine whether Kif5b has a similar function or
another unique function during cell division.
One seemingly contradictory result found in this study
was that islet mass was not affected (Fig. 8C) even though
-cell proliferation was inhibited in the Kif5b deﬁciency
mice. Further analysis of the pancreatic sections found
that islet number was signiﬁcantly increased (Fig. 8D). There-
fore, it is possible that the impaired -cell function in
Kif5b-insKO mice induce -cell neogenesis to provide a
compensatory effect, a process difﬁcult to be deﬁned and
more difﬁcult to be quantiﬁed at the molecular level (25,50).
In summary, by using Kif5b conditional knockout mice,
we have demonstrated that Kif5b is essential in the main-
tenance of normal -cell function. Kif5b ablation leads to
decreased insulin secretion and diminished glucose toler-
ance with decreased islet size in the pancreas. Our results
indicate that genetic or epigenetic alteration in Kinesin-1
or other related motor proteins may inherit a predisposi-
tion to develop diabetes.
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